SEARCH

SEARCH BY CITATION

References

  • 1
    Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:106674.
  • 2
    WHO, UNICEF, UNFPA, The World Bank. Maternal mortality in 2005: estimates developed by WHO, UNICEF, UNFPA, and the World Bank. In: World Health Organization, editor. WHO Press, World Health Organization. Geneva: World Health Organization; 2005. pp. 167, 23–27, 29–38.
  • 3
    Sloan NL, Durocher J, Aldrich T, et al. What measured blood loss tells us about postpartum bleeding: a systematic review. Br J Obstet Gynaecol 2010;117:788800.
  • 4
    WHO, UNFPA, UNICEF, World Bank. Reduction of maternal mortality, a joint WHO/UNFPA/UNICEF/World Bank Statement. World Health Organization. Geneva: World Health Organization; 1999.
  • 5
    Brabin BJ, Hakimi M, Pelletier D. An analysis of anemia and pregnancy – related maternal mortality. J Nutr 2001;131:60414.
  • 6
    Bharati P, Som S, Chakrabarty S, et al. Prevalence of anemia and its determinants among nonpregnant and pregnant women in India. Asia Pac J Public Health 2008;20:34759.
  • 7
    El-Refaey H, O’Brien P, Morafa W, et al. Misoprostol for the third stage of labour. Lancet 1996;347:1257.
  • 8
    Senior J, Marshall K, Sangha R, Clayton JK. In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br J Pharmacol 1993;108:5016.
  • 9
    Tang OS Schweer H Seyberth HW. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002 17:332336.
  • 10
    Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first- trimester medical abortion. Contraception 2006;74:2630.
  • 11
    Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2007;3:CD000494. DOI: 10.1002/14651858.CD000494.pub3.
  • 12
    Langebach C. Misoprostol in preventing postpartum haemorrhage: a meta-analysis. Int J Gynoecal Obstet 2006;92:108.
  • 13
    Winikoff B, Dabash R, Durocher J, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet 2010;16:375.
  • 14
    Walley RL, Wilson JB, Crane JM, et al. A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage of labour. BJOG 2000;107:11115.
  • 15
    Høj L, Cardoso P, Nielsen BB, et al. Effect of sublingual misoprostol on severe postpartum hemorrhage in a primary health centre in Guinea-Bissau: randomized double blind clinical trial. Br Med J 2005;331:7237.
  • 16
    Bugalho A, Daniel A, Faundes A, Cunha M. Misoprostol for prevention of postpartum hemorrhage. Int J Gynecol Obstet 2001;73:16.
  • 17
    Derman RJ Kodkany BS Goudar SS. Oral misoprostol in preventing postpartum hemorrhage in resource-poor communities: a randomized controlled trial. Lancet 2006;368:12481253.
  • 18
    Walraven G, Blum J, Dampha Y, et al. Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trial. Br J Obstet Gynaecol 2005;12:127783.
  • 19
    Parker KL, Schimmer BP. Pituitary hormones and their hypothalamic releasing hormones. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman: The pharmacologic basis of therapeutics. 11th edn. New York: McGraw-Hill, 2006, 14891510.
  • 20
    Amico JA, Seitchik J, Robinson AG. Studies of oxytocin in plasma of women during hypocontractile labor, J Clin Endocrinol Metab 1984;58:2749.
  • 21
    Hofmeyr GJ, Nikodem VC, de Jager M, Drakely A. Side-effects of oral misoprostol in the third stage of labour–a randomised placebo-controlled trial. S Afr Med J 2001;91:4325.
  • 22
    Hofmeyr GJ, Gülmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol 2008;22:102541.
  • 23
    WHO Department of Reproductive Health Research. WHO statement regarding the use of misoprostol for postpartum haemorrhage prevention and treatment. Geneva: World Health Organization, 2009.
  • 24
    Durocher J, Bynum J, León W, et al. High fever following postpartum administration of sublingual misoprostol. Br J Obstet Gynaecol 2010;117:84552.
  • 25
    Khan RU, El-Rafaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol 2003;101:96874.
  • 26
    Vimala N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet 2006;92:10610.
  • 27
    Singh G, Radhakrishnan G, Guleria K. Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int J Gynaecol Obstet 2009;107:1304.
  • 28
    Blum J, Winikoff B, Raghavan S, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet 2010;375:21723.
  • 29
    Creinin MD, Carbonell JL, Schwartz JL, et al. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception 1999;59:116.
  • 30
    Bellad M, D T, Ganachari M, Mallapur M. Sublingual (SL) powdered misoprostol (400 mcg) vs IM oxytocin (10 IU) for prevention of postpartum blood loss – a randomized controlled trial. Int J Gynecol Obstet 2009;107:S1245.
  • 31
    Weeks AD, Alia G, Vernon G, et al. Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial. Lancet 2010;9:375 Epub 2009 Dec 7.
  • 32
    Abdel-Aleem H, Singata M, Abdel-Aleem M, et al. Uterine massage to reduce postpartum hemorrhage after vaginal delivery. Int J Gynaecol Obstet 2010;111:326.
  • 33
    Hofmeyr GJ, Nikodem VC, de Jager M, Gelbart BR. A randomised placebo controlled trial of oral misoprostol in the third stage of labour. Br J Obstet Gynaecol 1998;105:9715.
  • 34
    Gülmezoglu AM, Villar J, Ngoc NTN, et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 2001;358:68995.
  • 35
    Penaranda W, Arrieta O, Yances B. Active mangement of the childbirth with sublingual misoprostol: a clinical controlled trial in the Hospital de Maternidad Rafael Calvo [Manjeo activo del alumbramiento con misoprostol sublingual: un estudio clinico controlado en el Hospital de Maternidad Rafael Calvo de Cartagena]. Rev Colomb Obstet y Gineco 2002;53:8792.
  • 36
    Vimala N, Mittal S, Kumar S, et al. Sublingual misoprostol versus methylergometrine for active management of the third stage of labor. Int J Gynaecol Obstet 2004;87:15.
  • 37
    Lam H, Tang O, Lee CP, Ho PC. A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. Acta Obstet Gynecol Scand 2004;83:64750.